


Lexitas Acquired by NovaQuest to Support Continued Growth and Capability Expansion



The global ophthalmology market is expected to reach \$64 billion in value by 2027, driven by a greater prevalence of eye disease due to population aging. As a result, demand for specialized capabilities to support and accelerate biopharmaceutical and medical device development is increasing, with only a limited number of CROs specializing in this area.

Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the anterior and posterior segments of ophthalmology. The

Company's therapeutic area expertise, relationships with ophthalmic KOLs and network of high-performing research sites made it an attractive acquisition opportunity for NovaQuest Private Equity, whose philosophy of providing strategic capital to growing clinical trial services providers in niche, specialized therapeutic areas makes them an ideal partner to support Lexitas' continued growth.

Crosstree helped Lexitas evaluate various potential financial partners and determine the best strategic fit. The resulting acquisition allows Lexitas management to accelerate the Company's growth trajectory with the support of a knowledgeable strategic partner with a track record of successful investments in CROs.

Crosstree helps its clients identify optimal transaction partners to enhance value for all stakeholders.

ABOUT LEXITAS



Lexitas is a full-service ophthalmic biopharmaceutical solutions company focused on providing end-to-end eyecare support and exceptional service to biopharma and medical device clients globally. The Company has delivered clinical research studies across a wide range of ophthalmic indications, including dry eye disease; glaucoma, cataracts, uveitis, pediatric myopia, diabetic macular edema, age-related macular degeneration, and retinitis pigmentosa, among others.

ABOUT NOVAQUEST



NQPE is a private equity firm that invests in lower middle market healthcare companies primarily in North America. The Firm invests in services and technology companies where a strategic partner and operating resources can accelerate growth, targeting companies in healthcare and pharmaceutical services industries. NQPE invests in the form of buyouts, growth equity, and recapitalizations.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER — BY THE NUMBERS AND BEYOND — IS CROSSTREE'S SPECIALTY.

Crosstree's [proven track record](#) of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Director

jason.layton@crosstreecapital.com

813-578-7109